Antisense oligonucleotide inhibition of ras
First Claim
1. An oligonucleotide 8 to 30 nucleotides in length which is targeted to a nucleic acid encoding human Ki-ras, wherein said oligonucleotide is capable of inhibiting Ki-ras expression, and wherein said oligonucleotide comprises at least an 8-nucleobase portion of SEQ ID NO:
- 20, 21, 22, 31, 32 or 33.
1 Assignment
0 Petitions
Accused Products
Abstract
Compositions and methods are provided for the modulation of ras expression. Oligonucleotides are provided which are targeted to nucleic acids encoding human ras. Oligonucleotides specifically hybridizable with mRNA encoding human H-ras, Ki-ras and N-ras are provided. Such oligonucleotides can be used for therapeutics and diagnostics as well as for research purposes. Methods are also disclosed for modulating ras gene expression in cells and tissues using the oligonucleotides provided, and for specific modulation of expression of activated ras. Methods for diagnosis, detection and treatment of conditions, or particular cancers, associated with ras are also disclosed.
-
Citations
15 Claims
-
1. An oligonucleotide 8 to 30 nucleotides in length which is targeted to a nucleic acid encoding human Ki-ras, wherein said oligonucleotide is capable of inhibiting Ki-ras expression, and wherein said oligonucleotide comprises at least an 8-nucleobase portion of SEQ ID NO:
- 20, 21, 22, 31, 32 or 33.
- View Dependent Claims (2, 3, 4, 5)
-
6. A method of modulating the expression of human Ki-ras comprising contacting tissues or cells containing a human Ki-ras gene with an effective amount of an oligonucleotide of 8 to 30 nucleotides in length which is targeted to a nucleic acid encoding human Ki-ras, wherein said oligonucleotide is capable of inhibiting Ki-ras expression, wherein said oligonucleotide comprises at least an 8-nucleobase portion of SEQ ID NO:
- 20, 21, 22, 26, 28, 31, 32 or 33 and whereby expression of Ki-ras is modulated.
- View Dependent Claims (13, 14, 15)
-
7. A method of inhibiting the proliferation of cancer cells comprising contacting cancer cells with an effective amount of an oligonucleotide 8 to 30 nucleotides in length which is targeted to a nucleic acid encoding human Ki-ras, wherein said oligonucleotide is capable of inhibiting Ki-ras expression, wherein said oligonucleotide comprises at least an 8-nucleobase portion of SEQ ID NO:
- 20, 21, 22, 26, 28, 31, 32 or 33 and, whereby proliferation of the cancer cells is inhibited.
-
8. A method of preventing or treating a condition arising from the activation of a Ki-ras oncogene comprising contacting an animal suspected of having a condition arising from the activation of a Ki-ras oncogene with an effective amount of an oligonucleotide 8 to 30 nucleotides in length which is targeted to a nucleic acid encoding human Ki-ras, wherein said oligonucleotide is capable of inhibiting Ki-ras expression, wherein said oligonucleotide comprises at least an 8-nucleobase portion of SEQ ID NO:
- 20, 21, 22, 26, 28, 31, 32 or 33 and, whereby said condition is prevented or treated.
- View Dependent Claims (9, 10, 11, 12)
Specification